Top Markets
#1 GoPlus Security GoPlus Security +28.68%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.66%
#3 Status Status +18.41%
#4 Wrapped NXM Wrapped NXM +14.62%
#5 BankrCoin BankrCoin +10.62%
#6 Ontology Gas Ontology Gas +9.82%
#7 Bedrock Bedrock +9.64%
#8 Pons Pons +8.94%
#9 DMT-NAT DMT-NAT +8.71%
#10 Dual Dual +7.48%
Coin of the day
GoPlus Security GoPlus Security
Settings
Language
ENGLISH
Currency
USD
Theme
Polydex Pharmaceuticals Limited Polydex Pharmaceuticals Limited

Polydex Pharmaceuticals Limited

POLXF
Rank in Stocks #33818
Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was... Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.
Share Price
$1.99
Last synced: 2023-08-07
Market Cap
$6.82M
Change (1 day)
0.30%
Change (1 year)
0.00%
Country
CA
Trade Polydex Pharmaceuticals Limited (POLXF)

Category

Healthcare
Operating Margin for Polydex Pharmaceuticals Limited (POLXF)
Operating Margin as of 2026 TTM: 0.00%
According to Polydex Pharmaceuticals Limited latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Polydex Pharmaceuticals Limited from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.